Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 6/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936494 | 0.82 | CYP3A4 (0.38) | KDM4EALDH1A1MAPT | |
| SCHEMBL13601850 | 0.78 | NQO2 (0.39) | NQO2ABL1KDM4EGAAMAPT | |
| SCHEMBL13697796 | 0.77 | KDM4E (0.36) | NQO2KDM4EGAAALDH1A1MAPT | |
| SCHEMBL13515354 | 0.76 | NQO2 (0.44) | NQO2ABL1KDM4EPOLBGAA | |
| SCHEMBL2936605 | 0.74 | NQO2 (0.48) | NQO2ABL1KDM4EPOLBGAA | |
| SCHEMBL25395312 | 0.72 | NR4A2 (0.41) | GAATSHRNR4A2ALDH1A1HSD17B10 | |
| SCHEMBL6185365 | 0.72 | KDM4E (0.44) | KDM4EPOLBGAAALDH1A1GLA | |
| SCHEMBL8802475 | 0.72 | KDM4E (0.54) | NQO2ABL1KDM4EGAATSHR | |
| SCHEMBL30591117 | 0.72 | NR4A2 (0.41) | GAATSHRNR4A2ALDH1A1HSD17B10 | |
| SCHEMBL21820606 | 0.71 | NQO2 (0.42) | NQO2KDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580785-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580785-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580785-B2 | Insecticides | SYNGENTA CROP PROTECTION LLC (US) | 2013-11-12 | — | — | US | disclosed |
| CN-101273029-B | Bicyclic bisamide derivatives and their use as pesticides | SYNGENTA PARTICIPATIONS AG (CH) | 2013-03-27 | — | — | CN | disclosed |
| EP-1919903-B1 | BICYCLIC BISAMIDE DERIVATIVES AND USE THEREOF AS INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090221587-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221587-A1 | NOVEL INSECTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1919903-A2 | BICYCLIC BISAMIDE DERIVATIVES AND USE THEREOF AS INSECTICIDES | Syngeta Participations AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007020050-A2 | BICYCLIC BISAMIDE DERIVATIVES AND USE THEREOF AS INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221587-A1 | NOVEL INSECTICIDES | DDT, CYP4F11, ACHE | NQO2 2386/4885ABL1 819/4885KDM4E 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.